Benzinga · Aug 26, 2026
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Boston Scientific reports a cyber incident disrupting global operations, limiting system access and affecting order processing and shipments.
NV
NYSE · NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
$45.61
Down-$0.65 (-1.41%)
Updated Aug 31, 2026, 6:53 AM
SID Score
6.8/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 223.45B
- P/E ratio
- 12.76
- Dividend yield
- 3.69%
- 52-week range
- $35.12 – $64.16
- Volume
- 8.5M
- Avg. volume
- 16.69M
Price performance
NVO price history
1M range · 20 trading sessions · Daily adjusted prices
NVO closed at $45.61 after 20 trading sessions, down 3.14% for the selected period.
- Last close
- $45.61
- Period change
- -3.14%
- Period low
- $44.28
- Period high
- $48.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $46.17 | $46.21 | $45.405 | $45.61 | 8.5M |
| Aug 27, 2026 | $45.97 | $46.33 | $45.70 | $46.26 | 13.02M |
| Aug 26, 2026 | $47.80 | $48.04 | $46.87 | $47.19 | 8.88M |
| Aug 25, 2026 | $47.84 | $48.66 | $47.56 | $48.66 | 15.53M |
| Aug 24, 2026 | $47.09 | $47.30 | $46.565 | $46.92 | 9.67M |
| Aug 21, 2026 | $46.35 | $47.165 | $46.34 | $46.74 | 10.91M |
| Aug 20, 2026 | $46.89 | $46.90 | $46.11 | $46.14 | 9.67M |
| Aug 19, 2026 | $46.01 | $47.195 | $45.841 | $46.48 | 19.51M |
| Aug 18, 2026 | $44.91 | $46.065 | $44.76 | $45.71 | 12.09M |
| Aug 17, 2026 | $45.18 | $45.45 | $44.68 | $44.88 | 14.63M |
| Aug 14, 2026 | $46.895 | $47.045 | $45.75 | $45.89 | 10.85M |
| Aug 13, 2026 | $45.96 | $46.785 | $45.73 | $46.72 | 10.19M |
| Aug 12, 2026 | $45.87 | $46.55 | $45.56 | $46.39 | 9.56M |
| Aug 11, 2026 | $47.45 | $47.67 | $46.93 | $47.17 | 7.83M |
| Aug 10, 2026 | $47.00 | $47.735 | $46.66 | $47.73 | 10.19M |
| Aug 7, 2026 | $47.145 | $47.50 | $46.73 | $47.26 | 12.08M |
| Aug 6, 2026 | $45.61 | $45.98 | $44.93 | $45.97 | 13.12M |
| Aug 5, 2026 | $44.81 | $45.72 | $44.38 | $44.53 | 22.28M |
| Aug 4, 2026 | $47.585 | $49.15 | $43.68 | $44.28 | 47.48M |
| Aug 3, 2026 | $47.00 | $47.195 | $46.185 | $47.09 | 11.86M |
Latest NVO news
The latest Smart Investors Daily articles mentioning NVO.
Stock researchCompany · Overview
NVO research
Overview
Company profile and research snapshot.
Company profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | BERENBERG | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Hold | — |
| Jul 12, 2026 | GUGGENHEIM SECURITIES LLC | Neutral | — |
| Jul 5, 2026 | EQUISIGHTS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 19, 2026
'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ
https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2
SeekingAlpha · Aug 12, 2026
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
SeekingAlpha · Aug 12, 2026
The Market Is (Still) Underestimating Novo Nordisk
AI research layers
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares traded at $45.61, reflecting significant downward pressure over multiple timeframes. Per SID market data, the stock declined 11.63% over the trailing one-month period and posted a steep 19.19% loss over the past year, underscoring sustained bearish momentum in the healthcare giant. The three-month return was essentially flat at 0.07%, suggesting a brief stabilization period before the recent selloff resumed. Technically, shares traded below both the 50-day moving average of $47.89 and the 200-day moving average of $46.41, confirming a bearish trend structure. The 14-day relative strength index registered at 40.4, approaching oversold territory but not yet signaling a reversal. According to Massive/Polygon data, average daily trading volume stood at approximately 16.69 million shares, indicating robust liquidity. The stock's beta of 0.352 reflects substantially lower volatility relative to the broader market, consistent with its defensive healthcare classification.
Novo Nordisk A/S Valuation Analysis
Novo Nordisk A/S carries a market capitalization of approximately $223.45 billion, positioning it among the largest healthcare companies globally. Per SID market data, the stock trades at a price-to-earnings ratio of 12.76, a notable discount compared to many large-cap pharmaceutical peers, potentially reflecting investor concerns about growth sustainability amid increasing GLP-1 competition. The PEG ratio stands at 2.05, according to SEC filings, indicating the current valuation relative to expected earnings growth remains elevated. The price-to-book ratio of 8.43 reflects the substantial premium the market assigns to the company's intangible assets, brand strength, and intellectual property portfolio. Novo Nordisk offers a dividend yield of 3.66%, providing meaningful income to shareholders during a period of capital depreciation. Within the healthcare sector, the combination of a compressed P/E ratio alongside a high price-to-book multiple highlights the market's nuanced assessment of near-term earnings risk versus long-term franchise value.
Smart Money Activity for NVO
Smart money indicators for Novo Nordisk A/S present a mixed picture, with the composite smart money score registering at 59 out of 100, generating a neutral signal per SID market data. Institutional activity represents the strongest component, scoring 23.0 out of 25 according to 13F institutional filings, indicating that major fund managers maintain substantial positions and continue to express confidence in the company's long-term fundamentals. Insider activity scored 12.5 out of 25 per SEC Form 4 filings, reflecting a moderate level of insider transactions that neither strongly confirms nor contradicts the current price trajectory. Dark pool activity registered at 11.5 out of 25, suggesting below-average institutional block trading interest at current price levels. Congressional trading activity scored 12 out of 25, showing limited but present engagement from lawmakers. The divergence between high institutional conviction and weaker dark pool and insider signals suggests large holders are maintaining existing positions rather than aggressively accumulating new shares during the recent drawdown period.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk A/S faces a series of upcoming earnings reports with consensus estimates reflecting stable expectations across all four quarters. According to analyst estimates compiled by SID, Wall Street projects earnings of $0.81 per share for each of the next four reporting periods, with dates clustered in August 2026. The first report is scheduled for August 28, 2026, followed by subsequent releases on August 25, August 21, and August 18, 2026. The uniform $0.81 estimate across all periods suggests analysts currently model consistent sequential performance without significant acceleration or deceleration in profitability. No actual results have been reported yet for these periods, leaving surprise data unavailable. Per company earnings reports, the flat earnings trajectory implied by consensus stands in contrast to the stock's 19.19% year-over-year price decline, suggesting the market may be pricing in downside risks beyond current analyst models. Investors will closely monitor whether competitive dynamics in the GLP-1 market impact reported figures.
Wall Street Analyst Ratings for NVO
Wall Street analyst sentiment toward Novo Nordisk A/S remains predominantly constructive, though recent activity reveals emerging caution. Per SID consensus data, three of the five most recent analyst actions maintained Buy ratings, including reiterations from Rothschild & Co Redburn and Berenberg on July 13, 2026, as well as Equisights on July 5, 2026. However, Jyske Bank downgraded NVO from Buy to Hold on July 13, 2026, representing a notable shift in conviction from the Danish financial institution. Guggenheim Securities LLC maintained its Neutral rating on July 12, 2026, according to Wall Street analyst reports, reflecting a wait-and-see approach at current valuation levels. The Jyske Bank downgrade is particularly significant as a domestic institution reassessing its outlook on Denmark's largest company. The distribution of ratings — three Buy, one Hold maintained, and one downgrade to Hold — indicates that while majority sentiment supports the stock, the bearish minority is growing amid the 11.63% one-month price decline and broader competitive uncertainties in the obesity therapeutics market.
